1. International Marketing Partner:
www.generics-asia.com
Produced by:
Life
Sciences
Media Partners:
REGISTER TODAY! Tel: +65 6508 2401
Develop Competitive Strategies for Pricing,
Portfolio Management & Market Access
@IBCPharmaAsia
Supporting Associations:
Pre-Conference Workshop • 11 November 2013
Go-to-Market Innovation: Increasing
Awareness, Access & Margins
Post-Conference Workshop • 14 November 2013
Biosimilars Entry for Generic Companies
2 0 1 3
ASIA
Shanti Shamdasani
Regional Director,
Government Affairs –
ASEAN,
Johnson & Johnson
Jingyi Yu
Manager, Generics &
Biosimilar Business,
Strategy & Business
Development,
Pfizer
Jose Ochave
Senior Vice President,
Business Development,
Unilab
2013 Speaker Panel Includes:
NEW
NEW
NEW
Debbie Pangan
Corporate Affairs Director,
The Generics Pharmacy
Richard Lonsdale
Regional Relationship
Manager (Asia-Pacific),
AXA Healthcare
Management
NEW
NEW
Latest Hot Themes This Year
Market Access Opportunities
Universal Health Insurance Scheme Updates
Drug Pricing Challenges
Regulatory & Product Registration Updates
Branded Generics Launches
Biosimilars Market Entry
Drug-Delivery Device Partnerships
11 – 14 November 2013 | Marriott Hotel, Singapore

2. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.generics-asia.com
8th
ASIA2013
CONFERENCE DAY ONE
Tuesday, 12 November 2013
08:30 Registration & Welcome Coffee
09:00 Chairperson’s Opening Remarks
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals,
USA
GENERICS MARKET OUTLOOK & MARKET ACCESS
09:10 The Generics Game Plan: Tackling the Increasing Trend
Towards Commoditization of the Pharma Market
• International and regional Asia outlook for the generics market
• Tapping into Asia’s economic growth and how pharma can position
to take advantage of it
• How are innovators positioning themselves against generics
companies? Will price drive market share?
• What options are available for generics companies to differentiate
their products in an increasingly competitive & commoditized
market?
Palash Mitra, Partner, Mckinsey
09:45 Identifying the Roadblocks & Navigating Regulatory
Pathways to Maximize Market Access Across Asia
• What are the key factors influencing product registration across
Southeast Asia?
• Regulatory issues – bioequivalence standards for generics
• Addressing the option of local or regional manufacturing vs. import
from overseas
Ng Cheng Tiang, Director, Regulatory, Teva
Pharmaceutical Industries
10:20 Morning Refreshments
10:50 Achieving Regulatory Harmonization in ASEAN Countries
– An Industry Perspective
• Implications of regulatory harmonization in ASEAN – is it possible
to have one standard applied across different countries?
• Where are we with regards to the implementation readiness on
the harmonized product standard and conformance amongst
ASEAN members?
• Will harmonization change the generics game for industry?
• What is the industry’s current position and how to work closer
with regulators for ASEAN harmonization?
Herlina Aziz, HeadofRegulatory&Quality, Janssen Indonesia
11:25 The Evolving Market Access Landscape in Asia: From Self-
Paying to Reimbursed
• Changes to the healthcare system environment
• How will the changes impact originators and generic companies
• The rise of health consumers
• Moving beyond price focus towards value
Jeff Weisel, Managing Director, Celadon Health Ventures
12:00 Accessing Southeast Asia’s Highest Potential Countries:
Indonesia & Vietnam. How will their Universal Insurance
Coverage Impact the Pharma and Generics Market?
• Outlining the government’s plans for universal health insurance
coverage in Indonesia and Vietnam starting in 2014
• What role can international and local pharma companies now play
in the Indonesian & Vietnamese market especially with
implemented pricing for drugs on the EDL?
• How will branded generics or generic competitors be impacted
by the changes? Where are the opportunities?
• What and where are the opportunities for partnerships/JVs/M&A
for local and international players?
Shanti Shamdasani, Regional Director, Government Affairs –
ASEAN, Johnson & Johnson
12:35 Networking Lunch
14:00 Are Evergreening Strategies Futile in Asia?
• With India’s government ruling against Novartis, is it even worth
having a patent?
• What commercial implications are there for both originators and
generic players?
• What other lifecycle management options should MNCs consider
in order to fight off generics?
Dr Mandar Kodgule, Associate Vice President & Head, Global
IP & Strategic Planning, Wockhardt
ACCESSING NEW GLOBAL MARKETS
14:35 US&EuropeMarketEntryOpportunitiesforAsianGenerics
Players
• 3 years since the introduction of Obamacare in the US, will Asian
generics companies stand to benefit from greater generics usage
in the West?
• Latest regulatory and product registration guidelines
• With trends of increasing pricing pressures from governments,
how can pharma brace themselves to better react to this?
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals,
USA
15:00 Which Markets Should Local Generic Companies Expand
Into?
• Expand regionally or head west?
• Is MENA region still a contender?
• Why regional generic companies have not traditionally done well
outside their own market
• Key elements to consider before expansion internally and externally
Imtiaz Razzaq, Head, Business Development, Getz Pharma
15:45 Afternoon Refreshments
UTILIZING STRATEGIC PARTNERSHIPSTO BUILD MARKET
SHARE IN THE COMPETITIVE GENERICS MARKET
16:15 Pfizer’s Partnership with Hisun Pharma
• How Pfizer is building market share in the Chinese domestic market
• Critical factors in the selection of the product portfolio from each
partner
• Improving sales and marketing outreach
• Key success factors in the multi-cultural collaboration
• On-going alliance management to ensure a successful partnership
Jingyi Yu, Manager, Generics & Biosimilar Business, Strategy &
Business Development, Pfizer
16:50 How Strategic Partnerships Can Build Market Share
through Product Differentiation and Improved Market
Access
• Should MNCs partner with local companies?
• Is there a future for partnerships with regional players?
• Will supergenerics change the dynamics in Asia and if so, what
can each player (CROs, CMOs, originators & generic companies)
contribute to the partnership?
Moderator:
Julien de Salaberry, Managing Director, The Propell Group,
Former Head of Strategy & Business Development, Asia Pacific,
Merck & Co
Panellists:
Dr Fangchen Lee, Chairman, YungShin Group
Dr Azizi Ayob, Medical/Scientific Director,
Questra Clinical Research
17:35 Chairperson’s Remarks and End of Conference Day One
PANELDISCUSSION

3. 09:00 Chairperson’s Opening Remarks & Recap
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals,
USA
EXPANDING GLOBAL PRESENCE & PRODUCT
PORTFOLIO TO REAP GREATER COMMERCIAL SUCCESS
09:20 Considerations for a Regional Generic Company Entering
into Biosimilars
• Assessing the possible product pipeline
• What are the opportunities and challenges of entry into biosimilars?
• Key factors to consider before entry
• Should companies purchase or invest in their own expansion?
Dr Milind Sabnis, Principal Consultant, Healthcare,
Frost & Sullivan
09:55 Investing in Supergenerics in order to Increase Portfolio
Profits
• What is the opportunity in supergenerics?
• Changing dosages vs changing delivery devices – which molecules
to consider before making the decision
• Key considerations before investing in supergenerics
• Should the local generic company in-house or outsource parts of
the development?
Dr Lida Kalantzi, Pharmacist, Product Evaluation & Design,
R&D, Pharmathen
10:30 Morning Refreshments
11:00 Enhancing Product Differentiation through Novel Drug
Delivery Technology
• Understanding the strategic alliance between drugs and delivery
devices
• Assessing Asia’s acceptance of various alternatives in delivery
methods
• How can device companies engage with local generic companies
to grow their current portfolio into supergenerics?
For speaker updates, please visit www.generics-asia.com
MARKETING & DISTRIBUTION
11:35 Creating the Right Generics Brand, Beyond Cost
• The Asian stakeholders' perception towards generics
• How can generic companies create the right mindset to foster
greater demand
• Key elements in creating a generic ‘brand’
• Can innovators still win within the generics space?
Graeme Read, EVP, Chief Strategy Officer, McCann Health
12:05 Networking Lunch
13:15 Raising Brand Awareness and Consumer Choice the
RiteMed Way
• Creating a uni-brand for OTC, ethical and innovative products
• A cost effective method of using media and advertising to promote
a corporate brand
• Changing how medication is bought: Switchability occurring at
patient level
Jose Ochave, Senior Vice President, Business Development,
Unilab
8th
ASIA2013
CONFERENCE DAY TWO
Wednesday, 13 November 2013
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.generics-asia.com
13:50 Gaining a Greater Perspective from Pharmacy
• How are prescribers differentiating between the various generic
options?
• Is it easy to obtain switchability?
• What tools are required by the marketing and sales teams to build
the client relationship with prescribers?
• Building the pharma distribution network and relationship
• What are the areas of interest in Asia?
• How to work with pharma to gain greater pricing differential
• Key points pharma needs to be aware of when dealing with payers
Debbie Pangan, Corporate Affairs Director,
The Generics Pharmacy
14:25 Insights into the Payer’s Perception of Generics
• What are the areas of interest due to under-coverage in Asia?
• What are the different models of insurance coverage in healthcare
available in Asia?
• Key points pharma needs to be aware of when dealing with payers
Richard Lonsdale, RegionalRelationshipManager(Asia-Pacific),
AXA Healthcare Management
15:00 Afternoon Refreshments
15:30 Distribution of Products to Remote Parts of Asia Ensuring
Increase in Patient Access
• Key elements in tropical Asia to consider in cold chain management
• What are the major logistical challenges?
• A variety of services – what do pharma look for in choosing a
partner
For Speaker updates, please visit www.generics-asia.com
16:05 How can Companies Stay Ahead in the Branded
Generics Race
• What are the perception differences of quality, price and safety in
Asia?
• Should companies invest in branding and charge a higher price
or compete in offering the lowest possible?
• Tailoring launch strategies in Asia to gain maximum exposure
Moderator:
Viren Mahurkar, Managing Director, HitchinRock Advisors,
Former Senior Vice President, Global Business Development,
Wockhardt
Panelists:
Thomas Runkel, Vice President, Asia Pacific, Actavis
Khai Meng Ang, Vice President, Asia, Hospira
Cheah Ming Loong, General Manager, Ethical Division,
Kotra Pharma
Dr Imran Khalid , Director, Marketing & Sales, Getz Pharma
16:50 Chairperson’s Closing Remarks and End of Conference
CLOSINGPANEL
“Very informative, well organized and
enlightening”
~ Krystal, Eisai Malaysia
“Event was very informative and I got
connected with many new people”
~ Mahmood, Getz Pharma

4. Richard DiCicco, Chairman, Harvest Moon
Pharmaceuticals USA, Inc
Rich co-founded in 2007, with a proven pipeline of products
developed since 1984, Harvest Moon Pharmaceutical (HMP)
develops and licenses-out to the trade, worldwide, complex
generic drug products, copy bio products and biosimilars.
Rich is a member of the Editorial Board of the Journal of
Generic Medicines, a member of the Licensing Executives Society and is
widely published in generics and biosimilars.
Dr Janet M McNicholas, Partner, Jones Day
Janet has headed the biotechnology patent practice at
McAndrew, Held and Malloy, the Life Sciences Patent Group
of Cooley Godward in Palo Alto and served as patent counsel
for XOMA, a biotechnology company known as a leader in
the development of therapeutic antibodies. Prior to practicing
law, Janet conducted research in immunology, molecular
biology, biochemistry and genetics at Stanford University and at the California
Institute of Technology through a post-doctoral fellowship.
8th
ASIA2013 WORKSHOPS
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.generics-asia.com
This half-day workshop will run from 13:30 to 17:00, with a mid-afternoon break. Registration begins 30 minutes before the workshop commences.
Pre-Conference Afternoon Workshop A l 11 November 2013
Go-to-Market Innovation: Increasing Awareness, Access & Margins
Workshop Objectives:
It is not the availability of drugs that is the issue in solving the Asia
disease burden. In fact, pharmaceutical products are readily available!
It is the immature healthcare infrastructure in these markets that
prevents available products reaching those in need. Overcoming these
infrastructure limitations and challenges requires drug manufacturers
to adapt or re-invent their business model.
The Go-to-Market Innovation workshop aims to address these and
other challenges in the pharmaceutical industry by going beyond the
product and taking a go-to-market perspective.
Looking at your existing and upcoming products, how could you
innovate the way these are brought to the market, thereby improving
awareness, access, margins and social responsibility? Through cross
industry examples, practical frameworks and real life case studies, the
participants will generate, discuss and assess innovative ideas to
change the dynamics of doing business in Asia.
Workshop Agenda:
Participants are encouraged to bring a list of emerging market
challenges they face and/or foresee to facilitate discussion
Share & discuss go-to-market developments and challenges in
Asia
How to innovate your way of doing business and go beyond
product differentiation
Broaden your thinking: learn from other industries
Break outs to generate innovative go-to-market ideas based on
real case studies and develop the high level business model / key
elements
Sharing of go-to-market ideas/business models and learnings
from breakouts session
Discussion on applicability and way forward for the identified go-
to-market innovations
Led By:
Julien de Salaberry, Managing Director, The Propell
Group, FormerHeadofStrategy&BusinessDevelopment,
Asia Pacific, Merck & Co
Julien is an experienced regional head and GM – a global
leader with a cross cultural mindset. He has had 15+ years in
healthcare with leading brands including Eli Lilly, Boston
Scientific, Baxter, GSK, Merck&Co.. Currently, Julien is an
advisor to startups and incubators in healthcare and technology in emerging
high growth markets.
Specialties: Business Model Strategy & Design, Commercial Innovation,
Inorganic & Organic Growth, Mergers & Acquisitions / Joint Ventures,
Turnaround, Multicultural Team Leadership
Nynke Kinderman, Innovation Consultant
Nynke is an experienced business innovation and market
development consultant with strong expertise in the field of
new business models. She possess a cross industry
perspective due to driving the go-to-market for leading MNCs
in amongst others financial services, utilities, consumer goods
and automotive.
Specialties: Business Model Innovation and Design, Market Entry, Investment
analysis, Training & Development on Innovation Capabilities
Post-Conference Full-Day Workshop B l 14 November 2013
Biosimilars Entry for Generic Companies
An overview of the challenges and opportunities in the biosimilars
market
Selecting country of origin in certain market tenders to facilitate
registration
Impact of second generation molecules being launched prior to
availability of first generation biosimilars
How important is interchangeability and substitution for the
second wave of biosimilars?
• In chronic indications of RA, Psoriasis and Crohns?
• In oncology indications?
What future molecules should be considered for development
and where could there be synergies?
What are the various market entry/launch strategies in
pharmerging Asia?
Gauging originators’ response to biosimilars
Litigation?
Authorized biosimilars?
Strategic pricing?
Life cycle management strategies?
Implications of such actions in MENA, LATAM and APAC emerging
markets
What is the recommended legal due-diligence needed before
entry into pharmerging countries?
Whataretheessentialsinordertosuccessfullydevelopandlaunch
biosimilars?
This full-day workshop will run from 09:00-17:00, with mid-morning and afternoon breaks and lunch. Registration begins 30 minutes before the
workshop commences.
Led By:

5. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.generics-asia.com
Countries Represented
• Do you find difficulty in reaching senior decision makers and
successfully stimulating interest for your services?
• Are you trying to raise awareness of the value of your company’s
expertise and services?
• Or are you finding it difficult to differentiate your company from
your competition?
Who You’ll Meet
■ Regulatory Authorities(government) &
Ministry of Health 2%
■ Generic & Biosimilars Companies 45%
■ Innovator Pharma Companies 35%
■ Drug Delivery Companies 5%
■ Contract Research Organizations /
Analytical Labs 2%
■ Contract Manufacturing Organizations 5%
■ API companies 2%
■ Pharma Wholesalers & Distributors 2%
■ Others 2%
• Business Development & Strategy
• Government Affairs
• Marketing
• IP /Legal Counsel
• Sales
• Regulatory Affairs
• Product Development
• Strategy Planning & Development
• Licensing
• Commercial
• Formulations
• Procurement / Sourcing
• External Manufacturing
• Clinical Trials
• Collaborative Research
• CMO Account Management
• Quality Assurance
• Technology Transfer
CEOs, CSOs, Managing Directors,
Director, VP, Head of
Sample Past Attending Companies
ACTAVIS • ASTRAZENECA • BAYER • BECTON DICKINSON • BOEHRINGER INGELHEIM
GMBH • CCM PHARMACEUTICALS • CENTRUM CAPITAL • DR REDDY’S LABORATORIES
• DRUG HOUSES OF AUSTRALIA • EISAI • ELI LILLY • GENENTECH • GETZ PHARMA •
GLAXOSMITHKLINE • HANWHA CHEMICAL • HOSPIRA • HOVID • JCR PHARMACEUTICALS
• MYLAN • MERCK • NIPPON KAYAKU • NORTH CHINA PHARMACEUTICAL GROUP
CORPORATION • PFIZER • PHARMANIAGA • PT DEXA MEDICA • PT KALBE • RANBAXY
•SANDOZ•SANOFI-AVENTIS•SAKEDA•UNITEDLABORATORIESINC•USV•WOCKHARDT
• ZUELLIG PHARMA • ZYDUS CADILA HEALTHCARE
North Asia 12%
China 3%
Taiwan 6%
Hong Kong 4%
Indonesia 10%
Singapore 35%
Thailand 8%
Malaysia 15%
India 8%
What you need is a branding opportunity at this event! Increase your
reach through our extensive marketing campaign, targeted at your
qualified business audience.
For information about placing your brand & profile top-of-mind to
key buyers, contact Yvonne Leong, Business Development Manager
on Tel: + 65 6508 2489 / yvonne.leong@ibcasia.com.sg
Sponsorship Opportunities
Raise awareness for your services available to Asian pharmaceuticals!
11 – 14 November 2013
Sheraton Towers, Singapore
What’s New This Year
The emergence of greater national insurance coverage
across Asia
Lifecycle management & post-pay-for-delay evergreening
strategies
Strategic partnerships for growth
Challenges and opportunities in supergenerics & biosimilars
Branding strategies that deliver results
With austerity measures being put in place globally, greater
emphasis on generics comes to light in terms of cost savings.
In Asia, countries are gearing towards greater regulatory
harmonization and universal health coverage. IBC’s 8th
Generics Asia 2013, the longest running conference bringing
together East and West, innovators and generics companies,
will discuss strategies and commercial opportunities from the
generic spending boom!
Why You Need To Attend in 2013
Annual global spending on medicines will reach nearly $1.2 trillion in 2016
Global generic spending will increase from $242Bn in 2012 to $400-430Bn by 2016 – an increase of 77%
*IMS Health 2013
Develop Competitive Strategies for Pricing, Portfolio
Management & Market Access
2 0 1 3
ASIA
8th

6. ENJOY SUBSTANTIAL SAVINGS WITH
OUR MULTIPLE BOOKING DISCOUNT!
Early Bird Rate
Register & pay on or
before 6 Sep 2013
FEE PER DELEGATE
Special Rate
Register & pay on or
before 4 Oct 2013
Group Rate
(3 or more delegates)
Normal Rate
Register & pay after
4 Oct 2013
REGISTER NOW! FAX BACK TO +65 6508 2407
HOTEL INFORMATION
DATA PROTECTION
PAYMENT TERMS
CANCELLATIONS / SUBSTITUTION
IMPORTANT NOTE
This label contains your priority booking code. To expedite registration, please do not remove label. If you have
already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not
available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.
6 EASY WAYS TO REGISTER
Email
register@ibcasia.com.sg
Customer Service Hotline
+65 6508 2401
Fax
+65 6508 2407
Web
www.generics-asia.com
❑ Yes! I/We will attend the 8th Generics Asia 2013 | 11 – 14 November 2013, Marriott Hotel, Singapore
REGNO.200108203N
Who is Head of your Department?
Who is Head of Training?
Company Information
Company Name:
Address:
Main Business/Activity:
Postal Code:
8th Generics Asia 2013
❑ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.
RESERVE YOUR PLACE TODAY!
CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at
www.generics-asia.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name and
details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest
confidence, please do not send payment details by email.
Credit card contact: Department:
Direct phone number: Email:
P46227
Payment Method (Please tick:) ❑ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
❑ I am paying by bank transfer (copy attached)
❑ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
Payment must be received 10 business days prior to the event. To
take advantage of discounts with an expiry date, registration and
payment must be received by the cut-off date.
• Payment by bankers draft or cheque in S$ or US$ should be
made in favour of “IBC Asia (S) Pte Ltd” and mailed to:
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset #10-06
Singapore 238164
Attn: The Accounts Receivable Team
• Payment by bank transfer in S$ or US$ made payable to:
IBC Asia (S) Pte Ltd
A/C No.:147-059513-001 (S$)
A/C No.:260-457866-178 (US$)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building
Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232
• Payment by Credit Card (AMEX, VISA or MasterCard).
The best way to pay by credit card is through our secure portal
built into the website. To pay by phone please indicate the
contact name and details below and our Customer Services
Team will call within 24 hours to take payment. Please do not
send credit card information by email.
SAVE WITH THE
EARLY BIRD &
SPECIAL RATES!
❑ 2 Day Conference only
If undelivered, please return to:
111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: +65 6508 2408
Please photocopy for additional delegates
FREE
GROUP DISCOUNT
Delegate 1 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 2 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 3 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 4 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
SGD 2,595 SGD 2,795 SGD 2,995 SGD 2,495
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time. Fee
stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
• A 7% Goods & Services Tax (GST) is applicable to all Singapore based companies for Singapore venue.
The personal information entered during your registration/order, or
provided by you, will be held on a database and may be shared
with companies in the Informa Group in the UK and internationally.
Occasionally, your details may be obtained from or shared with
external companies who wish to communicate with you offers
related to your business activities. If you do not wish your details
to be used for this purpose, please contact our Database Department
at Email: database@ibcasia.com.sg, Tel: +65 6508 2400 or Fax:
+65 6508 2408.
Should you be unable to attend, a substitute delegate is welcome
at no extra charge. Cancellations must be received in writing at
least 10 business days before the start of the event, to receive a
refund less 10% processing fee per registration. The company
regrets that no refund will be made available for cancellation
notifications received less than 10 business days before the event.
Please quote the name of the delegate, event title and invoice
number on the advice when remitting payment. Bank charges are
to be deducted from participating organisations own accounts.
Please fax your payment details (copy of remittance advice, cheque
or draft to +65 6508 2407).
Attendance will only be permitted upon receipt of full payment.
Participants wishing to register at the door are responsible to ensure
all details are as published. IBC assumes no further liability or
obligation, beyond the refund of the paid registration fee, in the
event of postponement or cancellation by IBC.
SGD 3,695 SGD 3,895 SGD 4,095 SGD 3,595❑ 3.5 Day Package:
Conference + Workshops A + B
MAIL the attached registration form with your
cheque to IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset
#10-06, Singapore 238164
Scan the QR Code
with your smartphone
and register today
SGD 3,395 SGD 3,595 SGD 3,795 SGD 3,295❑ 3 Day Package:
Conference + Workshop B
SGD 2,995 SGD 3,195 SGD 3,395 SGD 2,895❑ 2.5 Day Package:
Conference + Workshop A
GROUP BONUS – Register 3 Delegates from the same company and the 4th Delegate attends FREE!
Marriott Hotel, Singapore
320 Orchard Road, Singapore 238865
DID: +65 6735 5800
Fax: +65 6735 9800
Contact Person: Peiqin Chua
Email: peiqin.chua@marriott.com